Shares of ADMA Biologics Inc. (ADMA) have surged over the past year, driven by increased sales of its immunoglobulin products, a strategic advantage with no tariff-related challenges, and a promising regulatory update that enhances production capabilities and accelerates pipeline development.
This commercial-stage company develops specialty plasma-derived products for the prevention and treatment of infectious diseases in immunocompromised and other patients at risk for infection.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com